Takeda Pharmaceutical (TAK) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $19.45, +2.31% vs the prior close of $19.01.
- Volume 4.39M shares, 1.7x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
TAK rises 2.3% to $19.45, a 52-week high. Closed at $19.45, +2.31% vs the prior close of $19.01. Day range $19.45–$19.89, opened at $19.58.
TAK daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — TAK rises 2.3% to $19.45, a 52-week high
- Closed at $19.45, +2.31% vs the prior close of $19.01. Day range $19.45–$19.89, opened at $19.58.
- Volume was 4.39M shares, 1.7x its 50-day average of 2.57M.
- Price is +6.4% vs its 50-day average ($18.28) and +12.3% vs its 200-day average ($17.32).
- 52-week range $12.99–$19.89; today's close sits at 94% of that range, 2.2% below the 52-week high.
Oct 14, 2026 — TAK rises 2.6% to $19.01 on 1.8x normal volume
- Closed at $19.01, +2.65% vs the prior close of $18.52. Day range $18.57–$19.04, opened at $18.63.
- Volume was 4.68M shares, 1.8x its 50-day average of 2.60M — unusually heavy trading.
- Price is +4.3% vs its 50-day average ($18.23) and +9.9% vs its 200-day average ($17.30).
- 52-week range $12.99–$19.10; today's close sits at 99% of that range, 0.5% below the 52-week high.
Oct 13, 2026 — TAK dips 0.9% to $18.52
- Closed at $18.52, -0.86% vs the prior close of $18.68. Day range $18.52–$18.82, opened at $18.73.
- Volume was 2.92M shares, 1.1x its 50-day average of 2.60M.
- Price is +1.9% vs its 50-day average ($18.18) and +7.1% vs its 200-day average ($17.28).
- 52-week range $12.99–$19.10; today's close sits at 91% of that range, 3.0% below the 52-week high.
Oct 12, 2026 — TAK ends flat (-0.3%) to $18.68
- Closed at $18.68, -0.27% vs the prior close of $18.73. Day range $18.66–$18.79, opened at $18.79.
- Volume was 1.91M shares, 0.7x its 50-day average of 2.65M.
- Price is +3.0% vs its 50-day average ($18.14) and +8.2% vs its 200-day average ($17.27).
- 52-week range $12.99–$19.10; today's close sits at 93% of that range, 2.2% below the 52-week high.
Oct 9, 2026 — TAK rises 1.1% to $18.73, 4 up days in a row
- Closed at $18.73, +1.13% vs the prior close of $18.52. Day range $18.37–$18.76, opened at $18.37.
- Volume was 2.04M shares, 0.8x its 50-day average of 2.72M.
- Price is +3.4% vs its 50-day average ($18.11) and +8.6% vs its 200-day average ($17.25).
- 52-week range $12.99–$19.10; today's close sits at 94% of that range, 1.9% below the 52-week high.
- That makes 4 straight gains.
Oct 8, 2026 — TAK rises 0.8% to $18.52, 3 up days in a row
- Closed at $18.52, +0.82% vs the prior close of $18.37. Day range $18.22–$18.52, opened at $18.39.
- Volume was 3.51M shares, 1.3x its 50-day average of 2.75M.
- Price is +2.4% vs its 50-day average ($18.08) and +7.5% vs its 200-day average ($17.24).
- 52-week range $12.99–$19.10; today's close sits at 91% of that range, 3.0% below the 52-week high.
- That makes 3 straight gains.
Oct 7, 2026 — TAK rises 1.5% to $18.37
- Closed at $18.37, +1.49% vs the prior close of $18.10. Day range $18.14–$18.46, opened at $18.14.
- Volume was 2.56M shares, 0.9x its 50-day average of 2.78M.
- Price is +1.7% vs its 50-day average ($18.07) and +6.7% vs its 200-day average ($17.22).
- 52-week range $12.99–$19.10; today's close sits at 88% of that range, 3.8% below the 52-week high.
Oct 6, 2026 — TAK rises 1.6% to $18.10
- Closed at $18.10, +1.63% vs the prior close of $17.81. Day range $17.96–$18.18, opened at $17.97.
- Volume was 3.10M shares, 1.1x its 50-day average of 2.79M.
- Price is +0.3% vs its 50-day average ($18.05) and +5.2% vs its 200-day average ($17.20).
- 52-week range $12.99–$19.10; today's close sits at 84% of that range, 5.2% below the 52-week high.
Oct 5, 2026 — TAK ends flat (-0.3%) to $17.81, a 1-month low, 5 down days in a row
- Closed at $17.81, -0.28% vs the prior close of $17.86. Day range $17.75–$17.91, opened at $17.78.
- Volume was 3.40M shares, 1.2x its 50-day average of 2.79M.
- Price is -1.3% vs its 50-day average ($18.04) and +3.7% vs its 200-day average ($17.18).
- 52-week range $12.99–$19.10; today's close sits at 79% of that range, 6.8% below the 52-week high.
- That makes 5 straight losses.
Oct 2, 2026 — TAK ends flat (+0.0%) to $17.86, 4 down days in a row
- Closed at $17.86, +0.00% vs the prior close of $17.86. Day range $17.78–$17.89, opened at $17.85.
- Volume was 2.13M shares, 0.8x its 50-day average of 2.82M.
- Price is -0.9% vs its 50-day average ($18.03) and +4.0% vs its 200-day average ($17.16).
- 52-week range $12.99–$19.10; today's close sits at 80% of that range, 6.5% below the 52-week high.
- That makes 4 straight losses.
TAK latest news & SEC filings
Every SEC filing by or about TAK in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 15, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Duprey Lauren Rusckowski sold 34,535 shares at $18.54 (≈$640.28K) on Sep 14, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 14, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 10, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Plump Andrew Stewart sold 116,191 shares at $18.49 (≈$2.15M) on Sep 2, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 2, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 31, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 21, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Plump Andrew Stewart sold 19,651 shares at $18.49 (≈$363.35K) on Aug 19, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 19, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Greenway Nicola Deidre Petal sold 12,980 shares at $18.11 (≈$235.07K) on Aug 18, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 6, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jul 30, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jul 9, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jul 8, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jun 29, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jun 26, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jun 24, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Things to know before you trade TAK
- How much it moves: over the last 20 sessions the average daily move was 1.09% (largest 2.6%).
- Liquidity: about 2.72M shares (≈$52.85M) trade per day on average.
- 52-week position: $19.45 vs a range of $12.99–$19.89 (94% of the range).
- Dividends: last ex-dividend date Mar 31, 2025 ($0.339/share); 0 payments in the past 12 months.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 20 sales; latest: Lauren Rusckowski Duprey sold 34,535 shares on Sep 14, 2026.
- Latest filings: 6-K Sep 14, 2026; 6-K Aug 31, 2026; 6-K Aug 6, 2026.
- Listing: NYSE · industry: Pharmaceutical Preparations.
TAK market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 19.58 | 19.89 | 19.45 | 19.45 | 4.39M |
| Oct 14, 2026 | 18.63 | 19.04 | 18.57 | 19.01 | 4.68M |
| Oct 13, 2026 | 18.73 | 18.82 | 18.52 | 18.52 | 2.92M |
| Oct 12, 2026 | 18.79 | 18.79 | 18.66 | 18.68 | 1.91M |
| Oct 9, 2026 | 18.37 | 18.76 | 18.37 | 18.73 | 2.04M |
| Oct 8, 2026 | 18.39 | 18.52 | 18.22 | 18.52 | 3.51M |
| Oct 7, 2026 | 18.14 | 18.46 | 18.14 | 18.37 | 2.56M |
| Oct 6, 2026 | 17.97 | 18.18 | 17.96 | 18.10 | 3.10M |
| Oct 5, 2026 | 17.78 | 17.91 | 17.75 | 17.81 | 3.40M |
| Oct 2, 2026 | 17.85 | 17.89 | 17.78 | 17.86 | 2.13M |
| Oct 1, 2026 | 18.07 | 18.13 | 17.86 | 17.86 | 2.40M |
| Sep 30, 2026 | 18.46 | 18.46 | 18.19 | 18.19 | 2.10M |
| Sep 29, 2026 | 18.56 | 18.58 | 18.37 | 18.51 | 2.42M |
| Sep 28, 2026 | 18.76 | 19.00 | 18.65 | 18.90 | 2.06M |
| Sep 25, 2026 | 18.82 | 18.91 | 18.77 | 18.86 | 2.74M |
| Sep 24, 2026 | 18.55 | 18.74 | 18.51 | 18.59 | 3.26M |
| Sep 23, 2026 | 18.86 | 18.98 | 18.78 | 18.81 | 2.61M |
| Sep 22, 2026 | 18.92 | 19.05 | 18.81 | 18.95 | 1.40M |
| Sep 21, 2026 | 18.98 | 18.99 | 18.84 | 18.89 | 1.76M |
| Sep 18, 2026 | 18.80 | 19.01 | 18.80 | 18.91 | 2.96M |
About Takeda Pharmaceutical
Takeda Pharmaceutical (TAK) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in TOKYO, Japan. Fiscal year ends —. SEC CIK 1395064.
TAK board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Bruce D Broussard | Director | Jul 6, 2026 |
| Jean Luc Butel | Director | Mar 18, 2026 |
| Ian T Clark | Director | Mar 18, 2026 |
| Yoshiaki Fujimori | Director | Mar 18, 2026 |
| Milano Furuta | Chief Financial Officer | Jul 6, 2026 |
| Steven Gillis | Director | Jul 6, 2026 |
| Koji Hatsukawa | Director | Mar 18, 2026 |
| Emiko Higashi | Director | Mar 18, 2026 |
| Masami Iijima | Director | Jul 6, 2026 |
| Julie So-Young Kim | President and CEO | Aug 12, 2026 |
| Koichiro Kimura | Director | Jul 6, 2026 |
| John Maraganore | Director | Jul 6, 2026 |
| Michel Bruno Orsinger | Director | Mar 18, 2026 |
| Andrew Stewart Plump | President, R&D | Sep 3, 2026 |
| Kimberly A. Reed | Director | Jul 6, 2026 |
| Paulus Stoffels | Director | Jul 6, 2026 |
| Miki Tsusaka | Director | Jul 6, 2026 |
| Christophe Pierre Weber | President and CEO | Apr 28, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Teresa Marie Bitetti | President, OBU | Aug 12, 2026 |
| Lauren Rusckowski Duprey | Chief Transformation Officer | Sep 15, 2026 |
| Awny Samaan Botros Farajallah | Chief Medical Officer | Aug 12, 2026 |
| Natalie Anne Marie Furney | Global General Counsel | Aug 12, 2026 |
| Milano Furuta | Chief Financial Officer | Jul 6, 2026 |
| Nicola Deidre Petal Greenway | Chief Human Resources Officer | Aug 19, 2026 |
| Ramy Riad Ahmed Ibrahim | President, PDT BU | Aug 12, 2026 |
| Julie So-Young Kim | President and CEO | Aug 12, 2026 |
| Asuka Miyabashira | President, Japan Pharma B.U. | Jul 6, 2026 |
| Rhonda Janice Pacheco | President, U.S. Business Unit | Aug 12, 2026 |
| Agosti Marcello Pignagnoli | Head, Strat. & Port. Dev | Aug 12, 2026 |
| Giles Richard Platford | President, IBU | Aug 12, 2026 |
| Andrew Stewart Plump | President, R&D | Sep 3, 2026 |
| Gabriele Ricci | Chief Data & Tech. Officer | Aug 12, 2026 |
| Elaine Mary Shannon | Pres., Global Supply & Quality | Aug 12, 2026 |
| Jennifer Marie Smoter | Chief Comm. & Gov. Officer | Jul 6, 2026 |
| Christophe Pierre Weber | President and CEO | Apr 28, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 14, 2026 | Lauren Rusckowski Duprey | Sale | 34,535 | $18.54 |
| Sep 2, 2026 | Andrew Stewart Plump | Sale | 116,191 | $18.49 |
| Aug 19, 2026 | Andrew Stewart Plump | Sale | 19,651 | $18.49 |
| Aug 18, 2026 | Nicola Deidre Petal Greenway | Sale | 12,980 | $18.11 |
| Aug 11, 2026 | Elaine Mary Shannon | Sale | 20,363 | $17.55 |
| Aug 10, 2026 | Julie So-Young Kim | Sale | 89,090 | $17.10 |
| Aug 10, 2026 | Ramy Riad Ahmed Ibrahim | Sale | 7,277 | $17.10 |
| Aug 10, 2026 | Elaine Mary Shannon | Sale | 3,978 | $17.10 |
| Aug 10, 2026 | Lauren Rusckowski Duprey | Sale | 47,586 | $17.10 |
| Aug 10, 2026 | Giles Richard Platford | Sale | 31,083 | $17.10 |
| Aug 10, 2026 | Gabriele Ricci | Sale | 25,088 | $17.10 |
| Aug 10, 2026 | Agosti Marcello Pignagnoli | Sale | 22,957 | $17.10 |
| Aug 10, 2026 | Natalie Anne Marie Furney | Sale | 30,868 | $17.10 |
| Aug 10, 2026 | Rhonda Janice Pacheco | Sale | 16,901 | $17.10 |
| Aug 10, 2026 | Nicola Deidre Petal Greenway | Sale | 33,628 | $17.51 |
TAK financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
TAK earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on TAK
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.